Cemiplimab and Fianlimab

Phase 2Monoclonal antibody

Cemiplimab and Fianlimab is one of 69 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaActive, not recruiting

Bladder CancerActive, not recruiting

Bladder Urothelial CarcinomaNot yet recruiting

Hepatocellular CarcinomaPhase 1

Active, not recruiting

Bladder CancerPhase 2

Active, not recruiting

Bladder Urothelial CarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Preclinical

1 2

Viread

Gilead

Preclinical

1 3

Cemiplimab and Fianlimab

MMemorial Sloan Kettering Cancer Center

Phase 2

1 4

Hepsera

Coreg

2 6

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 7

Doptelet

AAkarx

Preclinical

1 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 9

Statin

Bristol-Myers Squibb

Preclinical

1 10

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

Bladder Urothelial Carcinoma

NCT07414992

Q1 2035

Phase 1Not yet recruiting

Hepatocellular Carcinoma

NCT07365839

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma

Not yet recruiting·VVirginia Commonwealth University·Phase 1·NCT07365839·20 enrolled

Bladder Urothelial Carcinoma1 trial

Neoadjuvant STereotActic Body Radiotherapy and Cemiplimab With or Without Fianlimab for Cisplatin-Ineligible or Cisplatin-Declining Patients With Muscle-Invasive Bladder Cancer (NeoSTAR Bladder)

Not yet recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT07414992·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cemiplimab and Fianlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cemiplimab and Fianlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cemiplimab and Fianlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: MMemorial Sloan Kettering Cancer Center

Cemiplimab and Fianlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q1 2035

Trials by Indication[1]

Hepatocellular Carcinoma1 trial

Bladder Urothelial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News